The burden of myeloma: novel approaches to disease assessment

Research output: Contribution to journalReview articlepeer-review

Abstract

Novel therapies in multiple myeloma (MM) have increased the rates of conventional complete remission (CR) in patients. However, patients in CR can have highly heterogeneous outcomes. Novel and more sensitive methods of assessing residual disease burden after therapy will help prognosticate this group better and, ideally, allow individualized therapy adjustments based on response depth in the future. Here, we review novel bone marrow, peripheral blood, and imaging methods for assessing myeloma burden and discuss the opportunities and limitations of incorporating these in everyday clinical practice.

Original languageEnglish (US)
Pages (from-to)356-362
Number of pages7
JournalHematology. American Society of Hematology. Education Program
Volume2022
Issue number1
DOIs
StatePublished - Dec 9 2022

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'The burden of myeloma: novel approaches to disease assessment'. Together they form a unique fingerprint.

Cite this